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Limited data are available for adults undergoing unrelated donor (URD) BMT for AML using
chemotherapy-only preparative regimens. Previous studies incorporated irradiation,
included adults and children, and excluded secondary leukemia. Herein we report long-term
outcomes for adults with poor-prognostic AML receiving a novel regimen of busulfan
(16 mg/kg), cytarabine (8,000 mg/m2), and cyclophosphamide (120 mg/kg) (BAC), followed by
URD BMT. From June 1995 through October 2001, 45 adults were enrolled. Adverse features
included unfavorable cytogenetics (49%), secondary AML (47%), leukemia at transplant
(42%), and extramedullary disease (16%). At time of BMT, 23 were in remission (12 CR1)
while 22 had leukemia. Four (9%) died early. Acute and chronic GVHD rates were 44 and
67%, respectively. Seventeen (38%) were disease-free 52 months post-BMT; 13 were leuke-
mia-free (eight CR1) at transplant. Eleven relapsed. Three-year DFS and OS were 42 and
46%, respectively. DFS and OS were longer, and relapses less, for those in CR at time of
BMT. Secondary leukemia, cytogenetics, cell dose, and GVHD did not influence outcome. In
poor-risk AML, BAC provided cytoreduction comparable to reported TBI-containing regi-
mens, when administered for URD BMT. With decreasing treatment-related mortality, it is
justified to proceed early to URD BMT for patients with poor prognostic features. Am. J.
Hematol. 82:6–14, 2007. VC 2006 Wiley-Liss, Inc.
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INTRODUCTION
Allogeneic bone marrow transplantation (BMT)
from related donors is an established and effective
treatment for many adults with acute myelogene-
ous leukemia (AML). For those patients without a
matched related donor, transplantation using a
HLA-matched unrelated donor (URD) is a viable
option for two-thirds of patients requesting a donor
through the National Marrow Donor Program
(NMDP). To date, most of the published data for
patients with AML requiring an URD BMT have
been derived from relatively small pilot studies dem-
onstrating feasibility in terms of engraftment and
toxicity [1–6]. The majority of studies incorporated
a total body irradiation (TBI)-containing prepara-
tive regimen, included both adults and children as
subjects, often excluded secondary leukemia, and
were published with short follow-up. Despite aggres-
sive therapy, relapse remains a major cause of treat-
ment failure for those undergoing transplantation
with active disease.
In 1983, Santos et al. developed a chemotherapy-
only preparative regimen of busulfan and cyclophos-
phamide (200 mg/kg) (BU/CY-4), and demonstrated
efficacy comparable to TBI-containing regimens for
patients with AML [7]. In an effort to ameliorate
toxicities seen with BU/CY-4, Tutschka et al. signi-
ficantly reduced the dosage of cyclophosphamide
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(120 mg/kg) without compromising treatment out-
come (BU/CY-2) [8]. In the early 1990s, four random-
ized trials compared BU/CY with cyclophosphamide
and TBI (CY/TBI) in related allogeneic transplanta-
tion for myeloid (all trials) and lymphoid (one trial)
malignancies [9–12]. Two trials demonstrated im-
proved disease-free survival (DFS) with CY/TBI
[9,10], while the other two did not [11,12]. A meta-
analysis of these four trials, with follow-up ranging
from 24 to 42 months, concluded that CY/TBI
provided a nonsignificant trend toward improved
disease-free and overall survival (OS) [13]. With extended
follow-up of the 172 patients with AML participating
in these trials, 10-year DFS rates were 57% (95% CI,
44–70%) and 47% (95% CI, 36–58%) with CY/TBI
and BU/CY, respectively (P ¼ 0.05) [14].
Beginning in 1995, we chose to evaluate a novel
chemotherapy-only preparative regimen for adults
with primary and secondary AML undergoing
URD BMT. The BAC regimen, previously described
by our group in allogeneic related BMT, incorpo-
rates high-dose cytarabine with BU/CY-2 [15]. Re-
sistance to standard dose cytarabine can be multi-
factorial, including decreased membrane transport,
increased catabolism of the parent compound, and
decreased formation of phosphorylated derivatives
[16–18]. High-dose cytarabine can overcome resist-
ance by altering drug transport into cells [16]. As
cytarabine is one of the most effective agents used
for treatment of AML, the addition of high-dose
cytarabine to BU/CY might enhance cytoreduction
with manageable regimen-related toxicity. Herein we
demonstrate the favorable activity of BAC, compa-
rable to reported TBI-containing regimens, in adults




Adults with high-risk AML (de novo or second-
ary) and RAEB-t undergoing URD BMT were eligi-
ble. Patients in first complete remission (CR1) were
required to have at least one poor-risk feature:
unfavorable cytogenetics, secondary AML, or fail-
ure to attain remission with first induction chemo-
therapy. Karyotype abnormalities were categorized
as favorable [t(15;17), t(8;21), or inv(16)], intermedi-
ate (normal karyotype or a single abnormality not
classified as unfavorable), or unfavorable [del(5) or
del(7), abnormalities of chromosome 9 or 11, or
multiple clonal abnormalities] [19]. Eligibility re-
quirements included adequate organ function and
good performance scores. All patients gave written
informed consent. The study was approved by the
IRB at the University of Michigan.
Preparative Regimen
The BAC regimen included busulfan (4 mg/kg po
in divided doses daily on days 9 through 6; total
dose 16 mg/kg), cytarabine (2,000 mg/m2 twice daily
by 2-hr infusion on days 5 and 4; total dose
8,000 mg/m2), and cyclophosphamide (60 mg/kg
once daily by 2-hr infusion on days 3 and 2; total
dose 120 mg/kg) [15]. Phenytoin was given to pre-
vent busulfan-induced seizures and Mesna adminis-
tered to avoid hemorrhagic cystitis (100% of cyclo-
phosphamide dose). Intrathecal cytarabine (30 mg/
m2) was given for CNS prophylaxis pre-transplant
and on days 60 and 90 if the platelet count was
adequate.
Donor Bone Marrow Harvest or Leukapheresis,
Recipient Transplantation
Allogeneic cells were harvested from HLA A, B,
and DR identical or one-antigen mismatched
donors. Donors were matched at the antigen level at
the A and B loci and the allele level at DR. A mar-
row harvest target of 4.0  108 MNC/kg was col-
lected and administered without cryopreservation.
One patient received G-CSF primed PBSC. Alloge-
neic cells were infused 48 hr after completing chem-
otherapy (day 0). G-CSF (5 mg/kg/day sq) was
begun on day 6, and continued until an absolute
neutrophil count (ANC)  1,000/ml was achieved.
Graft-versus-Host Disease Prophylaxis,
Diagnosis, and Treatment
Patients received tacrolimus (0.03 mg/kg/day by
lean body weight) beginning day 1, with doses
adjusted to maintain blood levels of 10–20 ng/ml.
Dose reductions occurred if toxicity was observed.
Beginning day 56, tacrolimus was tapered 20% ev-
ery 4 weeks and discontinued on day 180 if GVHD
was not observed. Methotrexate was given on days
1, 3, 6, and 11 post-transplant. Short-course metho-
trexate (15 mg/m2 on day 1, 10 mg/m2 on days 3, 6,
and 11) was administered to the first nine patients,
after which minidose methotrexate (each dose 5 mg/
m2) was given to decrease mucositis. The decision to
administer methotrexate was determined by the se-
verity of mucositis, the amount of weight gain, the
presence of third-spacing, and renal and liver func-
tions on the day the drug was due.
Acute and chronic GVHD were graded by con-
sensus criteria [20,21]. Acute GVHD was treated ini-
tially with methylprednisolone (2 mg/kg/day) and
tacrolimus. Chronic GVHD was evaluated in those
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surviving at least 100 days, and treated as clinically
indicated.
Definitions and Statistical Analysis
Hematopoietic recovery was measured from day 0
to the first of three consecutive measurements of an
ANC  500/ml and platelets  20,000/ml, independ-
ent of transfusions. Marrow and blood evaluations
to determine disease and chimerism status were per-
formed on day 30 and as clinically warranted.
Descriptive statistics were reported as frequencies
or medians. OS and DFS were defined from day of
transplant to day of death or disease progression,
respectively. OS and DFS were estimated by the
Kaplan-Meier product limit method. Cumulative
incidences of acute GVHD, chronic GVHD, and
relapse were determined using the methodology of
Gooley [22], with variance estimates based upon the
methodology of Pepe [23]. The log-rank test com-
pared differences between patient subgroups. Cox
regression analyses were performed to determine
univariate associations of patient variables (second-
ary leukemia, unfavorable cytogenetics, disease sta-
tus at BMT, cell doses, HLA match, acute or
chronic GVHD) to disease outcomes (DFS, OS,
relapse). Acute and chronic GVHD were modeled
as time-varying covariates. P values were two-sided,
and P < 0.05 was significant.
RESULTS
Patient Characteristics (Table I)
From June 1995 through October 2001, 45 pa-
tients entered study. The median age at BMT was
44 years (range, 19–58). Twenty-one (47%) patients
had secondary AML: 12 with pre-existing myelodys-
plasia (MDS), 5 received prior chemoradiotherapy,
and 4 others had predisposing disorders (Kostman’s
syndrome, aplastic anemia, myeloproliferative dis-
ease, renal transplant). Of 8 patients with RAEB-t,
7 had transformed to acute leukemia while 1 had
20% blasts prior to BMT. Other poor risk features
included unfavorable cytogenetics (22 patients), fail-
ure to attain remission with first induction (16
patients), and extramedullary disease (7 patients).
Of the 12 patients in CR1, 10 had unfavorable cyto-
genetics, 9 had secondary AML, and 3 required
more than one induction to achieve CR.
Twenty-three patients achieved remission (12
CR1, 10 CR2, 1 CR3) to induction chemotherapy,
16 had refractory disease (8 primary induction fail-
ure, 8 refractory relapse), and three were untreated
at first relapse. Three did not receive any induction
(MDS, aplastic anemia, renal transplant). The me-
dian time from diagnosis to BMT was 8 months
(range, 2–54) for all patients. For those in CR1, the
median time to transplant was 6 months.
Engraftment and Toxicity
Thirty-six (80%) patients received cells from a 6/6
HLA-matched donor and nine from a 5/6 mismatched
donor. The median mononuclear and CD34 cell doses
infused were 2.4  108/kg (range, 1.1–4.4) and 3.5 
106/kg (range, 1.3–10.2), respectively.
There were four early (<day 30) treatment-related
deaths. Three patients died from GVHD (on days
58, 68, and 71) before platelet recovery and two
others had primary graft failure (one 5/6 HLA
match). Excluding those patients, the median days
TABLE I. Patient, Donor, and Disease Characteristics
Variable Number
Median age at BMT
Recipient 44 years (range, 19–58)
Donor 36 years (range, 21–54)
Gender of recipients 27 males/18 females
De novo AML 24 (53%)
Secondary AML 21 (47%)
Primary myelodysplasia 12
Chemoradiotherapy-induced 5
Kostman’s syndrome/aplastic anemia 2
Myeloproliferative disorder 1











Persistent leukemia 16 (36%)
No induction 3
Disease status at transplant
CR1 12 (26%)
CR2/CR3 10/1
Active leukemia 22 (48%)
Never treated 3
First relapse 3









MNC (108/kg) 2.4 (range, 1.1–4.4)
CD34 (106/kg) 3.5 (range, 1.3–10.2)
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to an ANC > 500/ml and platelets > 20,000/ml were
16 (range, 11–25) and 24 (range, 13–132), respectively.
Toxicities seen within 100 days post-transplant
included (No. of patients): moderate/severe mucosi-
tis (32), pneumonia/pneumonitis (11), hemorrhagic
cystitis (10), hepatic venoocclusive disease (5), and
renal insufficiency requiring hemodialysis (3). Infec-
tions during that period included (no. of patients):
bacteremia (23), c. difficile (5), CMV viremia (5),
fungal infections (4), varicella zoster (2), and atypi-
cal mycobacteria (2).
Acute and Chronic GVHD
Twenty patients developed grades II-IV acute
GVHD and 10 grades III-IV acute GVHD. The cu-
mulative incidences of grades II-IV and III-IV acute
GVHD were 44% (95% CI, 31–60%) and 22%
(95% CI, 11–42%), respectively (see Fig. 1). Nine
patients received a mismatched BMT; 2 died early
of toxicity and 1 never engrafted. Of the remaining
6 mismatched transplant patients, 4 developed acute
GVHD with 3 subsequently dying from grade IV
GVHD.
Thirty-one patients were alive without relapse at
day 100. Twenty patients developed chronic GVHD
(3 limited; 17 extensive), for a 1-year cumulative
incidence of 67% (95% CI, 51–81%) (see Fig. 2).
Of the 17 patients presently alive and disease-free,
12 had experienced GVHD (5 acute and 12 chronic
GVHD).
Survival and Relapse
Four (9%) patients died before day 30 of toxicity,
thus 41 were evaluable for response. Of 19 patients
undergoing BMT with active leukemia (excluding
three early deaths), 17 entered CR, 1 had primary
graft failure without leukemia, and 1 had persistent
blasts at day 30 marrow evaluation. The median
DFS and OS for the whole group were 389 and 535
days, respectively. DFS at 3 and 5 years were 42%
(95% CI, 30–59%) and 35% (95% CI, 22–54%),
respectively. OS at 3 and 5 years were 46% (95%
CI, 34–63%) and 35% (95% CI, 21–55%), respec-
tively (see Fig. 3).
Seventeen (38%) patients are alive and disease-
free at a median follow-up of 52 months (range, 28–
101) post-transplant. Disease status at BMT for the
survivors included 8 in CR1, 5 in CR2, and 4 with
leukemia (2 with refractory disease). Ten had unfav-
orable cytogenetics at initial diagnosis, 8 had sec-
ondary leukemia, 5 had failed first induction ther-
apy, 2 developed CNS relapse before BMT, and 1
received a HLA-mismatched transplant.
Eleven relapses appeared at a median of 163 days
(range, 40–521) post-transplant. Three relapses oc-
curred more than 1 year after BMT (at 13, 16, and
Fig. 1. (aGVHD): The cumulative incidence of grades II–IV acute GVHD was 44% (95% CI, 31–60%).
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17 months). The 3-year cumulative incidence of
relapse was estimated at 27% for the whole group
(see Fig. 4). All died subsequently from disease pro-
gression.
Twenty-eight (62%) patients have died, most from
disease progression (11 patients) (Table II). The rest
suffered either regimen-related complications (8
patients), GVHD (8 patients), or relapse of a previ-
ous malignancy (one sarcoma). All but one of nine
patients undergoing mismatched transplants have
died: 3 from toxicities, 3 from acute GVHD, and 2
from relapsed AML.
Fig. 4. (Rel Plot C): The 3-year cumulative incidence of
relapse for the whole group was 27%. The relapse rate
was significantly lower for those in CR1/CR2 at time of
BMT.
Fig. 2. (cGVHD): The 1-year cumulative incidence of chronic GVHD was 67% (95% CI, 51–81%).
Fig. 3. (Plot C): The 3-year overall survival for the whole
group was 46% (95% CI, 34–63%). OS was significantly
longer for those in CR1/CR2 at time of BMT.
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Univariate Analysis
DFS and OS were significantly longer for those
in CR1/CR2 (P ¼ 0.01 and 0.02, respectively), and
relapse rate lower (P ¼ 0.02), when compared to those
with leukemia at BMT. Survival was also enhanced for
those having a HLA-compatible donor (P ¼ 0.01).
There was a strong trend toward improved OS
with those in CR1 versus all others (P ¼ 0.08). Second-
ary leukemia, unfavorable cytogenetics, cell dose in-
fused, and acute or chronic GVHD did not influence
outcome.
DISCUSSION
There is a paucity of data reported for adults
undergoing URD BMT for primary and secondary
AML using chemotherapy-alone preparative regi-
mens. In this study, 45 adults received BAC with
URD BMT with the hope that adding cytarabine
might enhance cytoreduction with manageable toxic-
ity. Poor-prognostic features included: unfavorable
cytogenetics (49%), secondary AML (47%), active
leukemia at BMT (42%), lack of remission with first
induction (35%), and extramedullary disease (16%).
All 12 patients in CR1 at BMT demonstrated at
least one adverse feature, and eight had at least two.
The cumulative incidences of acute and chronic
GVHD were 44 and 67%, respectively. Seventeen
(38%) patients are alive and well at a median fol-
low-up of 52 months post-BMT; 13 were leukemia-
free (8 CR1, 5 CR2) at BMT. Three-year DFS and
OS were 42 and 46%, respectively. DFS and OS
were significantly longer for those in CR1/CR2, and
relapse rate lower, when compared to those with
leukemia at BMT. Survival was also significantly
better for those having a 6/6 HLA-matched donor.
Secondary leukemia, unfavorable cytogenetics, cell
dose infused, and GVHD did not influence out-
come. There are a number of observations made
during this study, and in a review of the literature,
that are worthy of comment.
First, the chemotherapy-only regimen BAC ap-
pears equally efficacious to CY/TBI when examined
by disease status at time of URD transplantation.
Two groups (NMDP and University of Washing-
ton, Seattle) have the largest outcomes data, pri-
marily employing CY/TBI as a preparative regimen.
As of June 2001, outcomes were available for 1,620
patients undergoing an URD BMT for AML (302
patients in CR1, 398 in CR2, and 920 in CR3 or
relapse) through the NMDP (www.marrow.org).
Approximately 81% received a TBI-containing regi-
men. Five-year survivals for those in CR1, CR2, or
with advanced disease were 32, 29, and 11%,
respectively. These data did not differentiate be-
tween primary and secondary AML. A retrospective
comparison of TBI-based or chemotherapy-only
preparative regimens given to 5,699 patients (1,342
with AML) undergoing URD transplantation re-
vealed similar relapse rates, non-relapse mortality,
and survival [24]. The Seattle group treated 161 pri-
mary AML patients (median age 30) with CY/TBI
(96%) and URD BMT [5,6]. Five-year DFS was
50% for patients in CR1, 28% for CR2, 19% for
primary induction failure, and 7% for relapse.
Patients in CR receiving marrow cell doses above
the median (3.5  108 MNC/kg) had the best DFS.
Although our study did not demonstrate an effect
of higher cell doses, CR status at BMT did impact
survival, with >60% of those in CR1 disease-free
4 years later.
Second, unfavorable cytogenetics may lose prog-
nostic significance if associated with CR status at time
of URD transplantation. At least 50% of adults with
de novo AML present with abnormal karyotypes,
which can be classified into three risk groups predic-
tive for response and survival after conventional
chemotherapy: favorable (CR 88%, OS 55%), inter-
mediate (CR 67%, OS 24%), and adverse (CR 32%,
OS 5%) [25]. The Medical Research Council AML 10
trial confirmed this risk stratification in children and
adults (aged 55 years) presenting with secondary as
well as de novo AML [26]. While such prognostic
indicators influence post-remission therapy, it re-
mains controversial whether allogeneic transplanta-
tion can overcome the poor prognosis associated with
unfavorable cytogenetics. For patients with AML in
CR1 presenting with adverse cytogenetics, some trials
have shown improved outcome for those undergoing
allogeneic BMT from related donors [27–29], while
others have not [30,31]. Data assessing karyotype and
outcome are lacking for URD BMT, in part due to re-
luctance to proceed to transplant in CR1 secondary
to expected high treatment-related mortality. In the
largest study available, cytogenetics did not influence
outcome for 161 primary AML patients undergoing
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URD BMT in Seattle [6]. Of the 22 patients in our
study with unfavorable cytogenetics, 8 of 12 trans-
planted in CR remain leukemia-free, compared with
only 2 of 10 with active leukemia. Three relapses were
observed and all had leukemia at BMT.
Third, URD transplantation may be an important
therapeutic modality for those with poor-risk fea-
tures in CR1. Four recent prospective trials random-
ized patients in CR1 to allogeneic BMT if a HLA-
related donor was available, or to either autologous
BMT or intensive chemotherapy [32–35]. Using an
intention-to-treat analysis, these trials demonstrated
a lower relapse rate for either transplant modality
(with the lowest relapses after allogeneic transplant)
when compared to chemotherapy alone. OS was not
improved after allogeneic BMT however, due to
increased treatment-related mortality, salvage with
BMT after relapse from chemotherapy, and a high
failure to comply with the randomized treatment,
such that only a minority of patients actually re-
ceived BMT. In the two trials for which karyotypes
were available [26,27], cytogenetic risk was prognos-
tic for outcome, however only the US intergroup
trial showed a survival benefit for patients with
adverse cytogenetics undergoing allogeneic BMT
[27]. The EORTC/GIMEMA AML-10 trial random-
ized patients in CR1 to either allogeneic stem cell
transplant (SCT) if a sibling donor was available or
to autologous SCT if no donor was found [29]. Both
relapse rate and DFS were significantly better for
patients undergoing allogeneic SCT. When assessed
by cytogenetic risk, DFS was similar for those with
good/intermediate risk cytogenetics, but markedly
improved (43.4% vs. 18.4%) for those with adverse
karyotype undergoing allogeneic SCT.
While related donor transplantation is justified
for CR1 patients with adverse prognostic features,
the appropriate post-remission strategy for patients
without a family donor remains undefined. There
are no large prospective trials evaluating autolo-
gous, unrelated donor, and/or cord blood stem cells
as alternative sources for this subset of patients.
Patients with poor-risk cytogenetics comprise a very
small subset of patients undergoing autologous
transplantation due to the difficulty achieving and
maintaining remission, as well as the inadequacy of
stem cell harvests secondary to underlying myelo-
dysplasia. Two recent analyses of registry data com-
pared outcomes using URD BMT with cord blood
transplantation for adults with leukemia [36,37]. In
both series, cord blood recipients were younger, had
more advanced disease, and experienced slower he-
matopoietic recovery due to lower cell doses. Al-
though both studies found no differences in risk
of relapse, neither recommended cord blood over
HLA-matched marrow in adults. With 1-year treat-
ment-related mortality decreasing (29% during the
years 1999–2003, NMDP data) and more precise
molecular HLA typing available, URD transplanta-
tion done early in the disease course becomes a fea-
sible option. Unlike CR2 patients for whom survival
is similar using unrelated or sibling donors, there
remains a 10–20% decrement in survival for CR1
patients undergoing URD when compared to sibling
BMT. In our small cohort of 12 CR1 patients re-
ceiving BAC, however, no relapses were observed
and eight remain alive and well a median of 52
months post-BMT.
Finally, URD BMT is not able to overcome the
dismal prognosis associated with leukemia refractory
to induction therapy. Those patients with overt
relapse at time of BMT do poorly, with only *10%
long-term survival noted despite transplantation.
Relapse remains the predominant cause of treatment
failure, but pronounced treatment-related toxicities
in patients with active disease contribute to the mor-
tality observed. Likewise, the Seattle group could
not discern an advantage for URD BMT in early
\untreated" relapse when compared with treatment-
refractory relapse (5-year DFS 12% vs. 5%, P ¼
0.2) [5]. Patients with >30% marrow blasts or any
peripheral blood blasts experienced mortality and
relapse that approached 100%. New therapeutic
modalities are desperately needed for this patient
population.
The role of reduced intensity conditioning regi-
mens for patients with AML undergoing URD trans-
plantation is at present undefined. These regimens
offer the potential for reduced regimen-related toxic-
ity, while depending to a greater extent on immuno-
logic-mediated cell killing for curative potential. De
Lima et al. performed a retrospective analysis com-
paring a truly nonmyeloablative regimen with a more
myelosuppressive treatment in AML and MDS
patients undergoing allogeneic transplantation [38].
The more myelosuppressive regimen was associated
with higher treatment-related mortality, but also a
significantly lower incidence of relapse and relapse-
related mortality. Survival was improved with either
regimen for patients in complete remission at time of
transplantation.
CONCLUSIONS
In summary, BAC is a highly effective preparative
regimen, comparable to Cy/TBI, for patients with
AML undergoing URD BMT. Disease status at
BMT was most prognostic for survival, with patients
in CR faring significantly better than those with
active leukemia. While secondary leukemia, adverse
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cytogenetics, higher cell doses, and GVHD did not
influence outcome in our study, one or more such
variables may achieve importance with greater
patient numbers. Perhaps the most important aspect
of this study was the favorable results observed for
patients transplanted in CR1. With decreasing treat-
ment-related mortality and the ability of patients to
withstand toxicities better with minimal residual dis-
ease, it is justified to proceed to URD BMT early for
patients with adverse prognostic factors. Until
improvement in the prevention and treatment of
GVHD becomes a reality, the role of URD BMT for
intermediate-risk AML requires exploration through
prospective clinical trials.
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